Researchers have discovered that the skeleton surrounding the nucleus of brain cells is dysfunctional in Alzheimer’s disease patients, which could lead to neuronal death. The study, “Lamin Dysfunction Mediates Neurodegeneration in Tauopathies,” was published in Current Biology. The lamin nucleoskeleton that surrounds the nucleus of cells is important in the…
News
As part of Allianz Championship week in Boca Raton, Florida, Allianz encouraged golf enthusiasts to share their favorite golf memories on Facebook, Twitter, Instagram and other social media sites — using the hashtag #AllianzBirdies — to raise awareness of the Alzheimer’s Association and its work. Two company groups — Allianz Life and Allianz Global…
Researchers at Harvard Medical School and the Koch Institute for Integrative Cancer Research at Massachusetts Institute of Technology have developed a system that allows them to study individual human neurons and other nervous system cells. Researchers have identified the subpopulations of cells responsible for the secretion of Alzheimer’s disease-relevant factors…
Tel Aviv University and Harvard researchers have found a new biomarker for cognitive aging and Alzheimer’s disease (AD). Diagnosing Alzheimer’s is not an easy task. The process employs measurements of memory impairment, cognitive skills, functional abilities, and behavioral changes, as well as brain imaging and analyses of the cerebrospinal fluid.
While there is abundant evidence that seafood consumption protects from the development of dementia, little is known about the effects of mercury — a heavy metal present in seafood — on the risk of Alzheimer’s disease. A new study shows that seafood mercury does not at all alter disease risk in older adults.
According to a new study from Imperial College London, England, long-term survivors of traumatic brain injury who develop brain issues have an increased number of amyloid-β (Aβ) plaques, a hallmark of Alzheimer’s disease. The research paper, “Amyloid pathology and axonal injury after brain trauma,” was recently published online in…
A study from Tel Aviv University found that the IGF-1 receptor, associated with an increased lifespan in mice, is mediating hyperactivity in the hippocampus of the brain. Hippocampal hyperactivity is linked to conditions that increase the risk for Alzheimer’s disease (AD), and the findings may pave the way for new AD treatments…
In a new study titled “Identification of Vulnerable Cell Types in Major Brain Disorders Using Single Cell Transcriptomes and Expression Weighted Cell Type Enrichment,” researchers pinpointed microglia cells in the brain as the specific cell type that likely triggers not only Alzheimer’s disease, but also multiple sclerosis.
A new study out of Michigan points to the pro nerve growth factor (proNGF) as a possible biomarker that could aid in the diagnosis of early Alzheimer’s disease (AD). The article, “Cerebrospinal fluid proNGF: A putative biomarker for early Alzheimer’s disease,“ appeared in the journal…
Tarrytown, New York-based PsychoGenics has announced its Line-41 mouse model of Alzheimer’s disease (AD) has obtained a license from the University of California, San Diego. This experimental model expresses human APP with the London (V717I) and Swedish (K670N/M671L) mutations under the murine-Thy-1 promoter control. PsychoGenics is a leader in providing preclinical…
Recent Posts
- FDA approves Auvelity to treat Alzheimer’s-related agitation May 4, 2026
- Daily Alzheimer’s pill slows brain shrinkage, boosts cognition April 6, 2026
- Researchers explore surgical treatment’s potential in Alzheimer’s March 2, 2026
- FDA fast-tracks expanded home injections for Alzheimer’s drug Leqembi February 2, 2026
- FDA decision on AXS-05 for Alzheimer’s agitation expected April 30 January 6, 2026